“R.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
By Fabian Cambero and Marco Aquino
SANTIAGO Y LIMA, 26 Aug (Reuters) – US pharmaceutical company Johnson and Johnson added Chile and Peru to Latin countries where it plans to conduct III trials for its COVID-19 vaccine, a university researcher said Monday.
He will participate 60,000 volunteers from Brazil, Chile, Colombia and Peru and will be coordinated through J.J.’s pharmaceutical unit. Janssen and local colleges.
Miguel O’Ryan of the Faculty of Medicine of the University of Chile, which will host the J-J trial, said that approval from the Chilean government is still needed.
“From our point of view, as soon as we have the vaccine available, in 3 weeks we can vaccinate the first volunteer,” he said.
“We have worked to expand the entire strategy and infrastructure to conduct a giant clinical trial.
Neither Janssen nor Chile’s Ministry of Health were available without delay for comment.
The J-J trial is one of many likely to take place in Chile. Sinovac is expected to launch a volunteer search soon, while the country is also in talks with CanSino, AstraZeneca Plc and Moderna Inc.
Mario Lopez, the Peruvian chancellor, told local radio on Tuesday night that J-J’s trial would also take place in Peru, giving additional details.
Peruvian President Martín Vizcarra has said in the past that tests will be conducted on the Chinese synopharma prototype and that he also hoped to verify until the end of August the trials of the ongoing astraZeneca vaccine at the University of Oxford.
The prototype uses “viral vectors” to generate immune responses to the technique adopted by the vaccine developers of Oxford and CanSino Biologics Inc. of China.
Brazil, Chile, Peru and Colombia have had viral infection rates in South America, making them exciting verification sites for vaccine developers because it is less difficult to download reliable verification effects in spaces with active maximum transmission and infection rates.
J-J’s head of vaccines had in the past told Reuters that his goal was to produce a billion doses of a possible vaccine next year and that he would inject the new coronavirus into healthy volunteers if there were not enough patients for final trials.
(Report through Fabian Cambero and Marco Aquino, written through Aislinn Laing; Editing via Lisa Shumaker)